Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Acute on Chronic Liver Failure Market Set to Grow by 2034 as Novel Therapeutic Approaches Enter Clinical Pipeline | DelveInsight

      DelveInsight_Logo

      News provided by

      DelveInsight Business Research, LLP

      Dec 08, 2025, 17:31 ET

      Share this article

      Share this article


      According to DelveInsight's analysis, the acute on chronic liver failure market is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as Genfit's VS-01, G1090N (reformulation of NTZ), SRT-015, CLM-022, VS-02-HE, Yaqrit's YAQ005, Grifols Therapeutics' ALBUTINE (Albumin 5%), and others, and healthcare spending in the 7MM.

      LAS VEGAS, Dec. 8, 2025 /PRNewswire/ -- DelveInsight's Acute on Chronic Liver Failure Market Insights report includes a comprehensive understanding of current treatment practices, acute on chronic liver failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). 

      Acute on Chronic Liver Failure Market Summary

      • The market size for acute on chronic liver failure in the leading markets is expected to grow significantly by 2034.
      • The United States accounted for the highest acute on chronic liver failure treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
      • In the US, infection-associated ACLF with more than two organ failures accounts for approximately 24% of cases.
      • Leading acute on chronic liver failure companies developing emerging therapies, such as Genfit, Yaqrit, Grifols Therapeutics, and others, are developing new therapy for acute on chronic liver failure that can be available in the acute on chronic liver failure market in the coming years. 
      • The promising acute on chronic liver failure therapies in clinical trials include VS-01, G1090N (reformulation of NTZ), SRT-015, CLM-022, VS-02-HE, YAQ005, ALBUTINE (Albumin 5%), and others.

      Discover the acute on chronic liver failure new treatment @ New Treatments for Acute on Chronic Liver Failure

      Key Factors Driving the Growth of the Acute on Chronic Liver Failure Market 

      Rising Chronic Liver Disease Prevalence 

      The increasing prevalence of chronic liver diseases such as cirrhosis, alcoholic liver disease, hepatitis (B and C), and MAFLD is leading to a larger pool of patients at risk for ACLF. This rise significantly contributes to the growing incidence of ACLF globally, which is a serious complication with high short-term mortality.

      Advances in Medical Treatments

      Recent progress in medical treatments, spanning innovative diagnostic tools, targeted drug therapies, and novel combination approaches, has led to improved outcomes for patients with ACLF. These advances include the introduction of new drug classes such as antivirals and immunosuppressants, along with ongoing developments in gene and cell-based therapies that aim to address unmet needs beyond traditional supportive care and organ transplantation.

      Rising ACLF Clinical Trial Activities

      The ACLF drug development landscape remains limited, with only a handful of companies actively advancing therapies. Genfit leads the field with four assets in its R&D pipeline, including programs currently in Phase 2. Its candidates—VS-01, G1090N (a reformulation of NTZ), SRT-015, CLM-022, and VS-02-HE—target distinct mechanisms and utilize complementary biological pathways. Beyond these, other notable ACLF candidates in clinical trials include YAQ005 (Yaqrit) and ALBUTEINE (albumin 5%) from Grifols Therapeutics, among others.

      Acute on Chronic Liver Failure Market Analysis

      ACLF remains a significant unmet medical need, with no approved therapies and minimal benefits from existing lifestyle-focused interventions. This multifactorial syndrome often develops in patients with underlying liver disorders such as alcohol-associated liver disease, drug-induced liver injury, or viral hepatitis. The absence of targeted pharmacological options underscores a substantial therapeutic void.

      This unmet need presents a compelling opportunity for pharmaceutical innovation. Developers of the first approved therapies for ACLF stand to gain early-mover advantages, including regulatory incentives, enhanced physician adoption, and favorable market positioning. Given the condition's progressive nature and high morbidity, there is strong justification for expedited drug development and regulatory acceleration to bring effective, targeted treatments to patients sooner.

      An increasing number of biopharmaceutical companies are investing in ACLF research programs, reflecting the growing recognition of the disease as a distinct and pressing clinical challenge. Focused investment in this area not only offers commercial potential but also promises to redefine patient outcomes by improving survival and quality of life. As understanding of ACLF's underlying mechanisms advances, the need for innovative, mechanism-based therapies tailored to its complex pathophysiology becomes ever more evident.

      To know more about acute on chronic liver failure treatment options, visit @ Approved Acute on Chronic Liver Failure Drugs

      Acute on Chronic Liver Failure Competitive Landscape

      The ACLF pipeline remains narrow, with only a few companies pursuing drug development. Genfit is leading with 4 assets in research and development, including those currently in Phase 2. VS-01, G1090N (reformulation of NTZ), SRT-015, CLM-022, and VS-02-HE are all based on differentiated mechanisms of actions leveraging complementary pathways. Apart from these, the other candidates in ACLF clinical trials include YAQ005 (Yaqrit) and ALBUTEINE (albumin 5%) (Grifols Therapeutics), among others.

      Genfit's VS-01 is an innovative liposomal intraperitoneal solution developed to facilitate the removal of various toxic metabolites, most notably ammonia, that accumulate in patients suffering from decompensated liver cirrhosis and hepatic encephalopathy. By promoting metabolic waste clearance, the therapy seeks to mitigate complications linked to liver impairment. The company is advancing its clinical program with the Phase IIa UNVEIL-IT study, which is evaluating the efficacy, safety, and tolerability of VS-01 in adults with ACLF.

      Grifols Therapeutics' Albumin 5% is a sterile intravenous preparation derived from pooled human plasma, containing primarily albumin. It acts as a plasma volume expander, aiding in the restoration and maintenance of blood volume and serum albumin levels. By replenishing circulating albumin, it helps sustain oncotic pressure and fluid equilibrium, making it an essential therapy for patients with hypovolemia or hypoalbuminemia.

      Currently, the product is being investigated in the Phase III APACHE clinical trial, which is evaluating the effect of plasma exchange with 5% human serum albumin on short-term survival in high-risk ACLF patients, with a focus on its potential to reduce in-hospital mortality.

      The anticipated launch of these emerging therapies are poised to transform the acute on chronic liver failure market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the acute on chronic liver failure market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about therapy for acute on chronic liver failure @ Acute on Chronic Liver Failure Clinical Trials 

      What is Acute on Chronic Liver Failure?

      Acute on chronic liver failure represents a rapid and severe worsening in individuals with chronic liver disease or cirrhosis, marked by acute hepatic decompensation and failure of one or more extrahepatic organs, leading to significant morbidity and mortality. However, its diagnosis remains difficult due to the lack of universally accepted criteria and validated biomarkers. Variations in definitions across EASL and other regional guidelines further hinder early detection and clinical decision-making. Therefore, standardized diagnostic frameworks and reliable predictive tools are urgently needed to improve timely intervention and patient outcomes.

      Acute on Chronic Liver Failure Epidemiology Segmentation

      The acute on chronic liver failure epidemiology section provides insights into the historical and current acute on chronic liver failure patient pool and forecasted trends for the leading markets. Our secondary analysis reveals that female sex is associated with an increased risk of developing ACLF compared to males. This finding underscores the importance of considering sex-based differences in risk assessment and highlights the need for tailored approaches to manage ACLF.

      The acute on chronic liver failure market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

      • Total Prevalent Cases of ACLF
      • Total Diagnosed Prevalent Cases of ACLF
      • Diagnosed Prevalent Cases of ACLF by Grade
      • Gender-specific Diagnosed Prevalent Cases of ACLF
      • Total Treated Cases of ACLF

      Acute on Chronic Liver Failure Market Report Metrics

      Details

      Study Period

      2020–2034

      Acute on Chronic Liver Failure Market Report Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Acute on Chronic Liver Failure Epidemiology Segmentation

      Total Prevalent Cases of ACLF, Total Diagnosed Prevalent Cases of ACLF, Diagnosed Prevalent Cases of ACLF by Grade, Gender-specific Diagnosed Prevalent Cases of ACLF, and Total Treated Cases of ACLF

      Key Acute on Chronic Liver Failure Companies

      Genfit, Yaqrit, Grifols Therapeutics, and others

      Key Acute on Chronic Liver Failure Therapies

      VS-01, G1090N (reformulation of NTZ), SRT-015, CLM-022, VS-02-HE, YAQ005, ALBUTINE (Albumin 5%), and others

      Scope of the Acute on Chronic Liver Failure Market Report

      • Therapeutic Assessment: Acute on Chronic Liver Failure current marketed and emerging therapies
      • Acute on Chronic Liver Failure Market Dynamics: Key Market Forecast Assumptions of Emerging Acute on Chronic Liver Failure Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Acute on Chronic Liver Failure Market Access and Reimbursement

      Download the report to understand which factors are driving acute on chronic liver failure therapeutics market trends @ Acute on Chronic Liver Failure Market Trends

      Table of Contents

      1

      Acute on Chronic Liver Failure Market Key Insights

      2

      Acute on Chronic Liver Failure Market Report Introduction

      3

      Executive Summary

      4

      Key Events

      5

      Epidemiology and Market Segmentation Methodology

      6

      Acute On Chronic Liver Failure (ACLF) Market Overview at a Glance in the 7MM

      6.1

      Emerging Therapies Analysis (By Phase, RoA, and Molecule Type)

      6.2

      Market Share (%) Distribution of Acute On Chronic Liver Failure (ACLF) by Therapies in 2024

      6.3

      Market Share (%) Distribution of Acute On Chronic Liver Failure (ACLF) by Therapies in 2034

      7

      Disease Background and Overview

      7.1

      Introduction

      7.2

      ACLF Causes

      7.3

      ACLF Pathophysiology

      7.4

      ACLF Symptoms

      7.5

      ACLF Diagnosis

      8

      ACLF Treatment and Management

      9

      Epidemiology and Patient Population

      9.1

      Key Findings

      9.2

      Assumptions and Rationale

      9.3

      The United States

      9.3.1

      Total Prevalent Cases of Acute On Chronic Liver Failure (ACLF) in the United States

      9.3.2

      Total Diagnosed Prevalent Cases of Acute On Chronic Liver Failure (ACLF) in the United States

      9.3.3

      Gender-specific Diagnosed Prevalent Cases of Acute On Chronic Liver Failure (ACLF) in the United States

      9.3.4

      Severity-specific (Grade 1–3) Cases of Acute On Chronic Liver Failure (ACLF) in the United States

      9.3.5

      Age-specific Diagnosed Prevalent Cases of Acute On Chronic Liver Failure (ACLF) in the United States

      9.3.6

      Cause-specific Diagnosed Prevalent Cases of Acute On Chronic Liver Failure (ACLF) in the United States

      9.3.7

      Diagnosed Prevalent Cases of Acute On Chronic Liver Failure (ACLF) by Liver Transplant Eligibility in the United States

      9.3.7.1

      Patients Eligible for Transplantation in the United States

      9.3.7.2

      Patients Ineligible or Awaiting Transplant in the United States

      9.4

      EU4 and the UK

      9.5

      Japan

      10

      Acute on Chronic Liver Failure Patient Journey

      11

      Emerging ACLF Therapies

      11.1

      Key Competitors

      11.2

      G1090N: Genfit

      11.2.1

      Product Description

      11.2.2

      Other Developmental Activities

      11.2.3

      Clinical Development

      11.2.3.1

      Clinical Trials Information

      11.2.4

      Safety and Efficacy

      11.2.5

      Analyst Views

      11.3

      YAQ005: Yaqrit

      List to be continued in the report…

      12

      Acute On Chronic Liver Failure Market: Seven Major Market Analysis

      12.1

      Key Findings

      12.2

      Acute on Chronic Liver Failure Market Outlook

      12.3

      Conjoint Analysis

      12.4

      Key Acute on Chronic Liver Failure Market Forecast Assumptions

      12.5

      Total Market Size of Acute On Chronic Liver Failure (ACLF) in the 7MM

      12.6

      Market Size of Acute On Chronic Liver Failure (ACLF) by Therapies in the 7MM

      12.7

      The United States ACLF Market Size

      12.7.1

      Total Market Size of Acute On Chronic Liver Failure (ACLF) in the United States

      12.7.2

      Market Size of Acute On Chronic Liver Failure (ACLF) by Therapies in the United States

      12.8

      EU4 and the UK ACLF Market Size

      12.9

      Japan ACLF Market Size

      13

      Key Opinion Leaders' Views on ACLF 

      14

      Acute on Chronic Liver Failure Market SWOT Analysis

      15

      Acute on Chronic Liver Failure Market Unmet Needs

      16

      Acute on Chronic Liver Failure Market Access and Reimbursement

      16.1

      The United States

      16.2

      In EU4 and the UK

      16.3

      Japan

      16.4

      Summary and Comparison of Market Access and Pricing Policy Developments in 2025

      16.5

      Market Access and Reimbursement of Acute On Chronic Liver Failure (ACLF)

      17

      Acronyms and Abbreviations

      18

      Bibliography

      19

      Acute on Chronic Liver Failure Market Report Methodology

      Related Reports

      Acute on Chronic Liver Failure Clinical Trial Analysis

      Acute on Chronic Liver Failure Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ACLF companies, including Genfit, Yaqrit, Grifols Therapeutics, among others.

      Liver Failure Market

      Liver Failure Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key liver failure companies, including Akaza Bioscience, Cellaion, VERSANTIS AG, Ocera Therapeutics, Steminent Biotherapeutics, GoLiver Therapeutics, Egetis Therapeutics, Genfit, Beijing Continent Pharmaceutical, LyGenesis, Alnylam Pharmaceuticals, Novartis, among others.

      Acute Kidney Injury Market

      Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AKI companies, including Alexion Pharmaceuticals, Alloksys Life Sciences, Am-pharma, Aptabio Therapeutics, Arch Biopartners, Guard Therapeutics, Novartis Pharmaceuticals, Ocelot Bio, Rediscovery Life Sciences, Renibus Therapeutics, River 2 Renal, among others.

      Metabolic Dysfunction-Associated Steatohepatitis Market

      Metabolic Dysfunction-Associated Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key MASH companies, including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected] 
      +14699457679
      www.delveinsight.com 

       Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.